Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft

ARTIVION, INC.

Net purchase price of $135M funded via $150M delayed draw term loan.
Contingent consideration up to $200M based on Nexus product performance, payable ~2 years post-close.
FDA approved Premarket Approval for Nexus branched endovascular stent graft system in April 2026.
Acquisition completes Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA devices.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.